A novel frameshift mutation in ADCK1 identified in a case of chronic fatigue syndrome successfully treated with oral 5-ALA/SFC.

导出 LinkOut

翻译打印收藏纠错

作者： Tomohiro,Koga ^[1] ; Kiyoshi,Kita ^[2] ; Junko,Okumura ^[3] ; Koh-Ichiro,Yoshiura ^[4] ; Atsushi,Kawakami ^[1]

作者单位： Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. ^[1] School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.;Department of Host-Defense Biochemistry, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan. ^[2] Department of Eco-epidemiology, NEKKEN, Nagasaki University, Nagasaki, Japan. ^[3] Department of Human Genetics, Nagasaki University Atomic Bomb Disease Institute, Nagasaki, Japan. ^[4]

关键词 5-aminolevulinic acid ADCK1 chronic fatigue syndrome mitochondrial dysfunction

DOI 10.1080/25785826.2024.2445399

PMID 39723997

发布时间 2024-12-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Immunological medicine

1-5页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A novel frameshift mutation in ADCK1 identified in a case of chronic fatigue syndrome successfully treated with oral 5-ALA/SFC.

Immunological medicine

相似文献

Immunological medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A novel frameshift mutation in ADCK1 identified in a case of chronic fatigue syndrome successfully treated with oral 5-ALA/SFC.

Immunological medicine

相似文献

Immunological medicine

相关期刊

检索历史清除